Increased secretion and expression of amylin in spontaneously diabetic Goto-Kakizaki rats treated with rhGLP-1 (7-36)

Acta Pharmacologica Sinica

Volumn 29, Issue 5, 2008, Pages 573-579

  Weng, Hong Bo ^a   Gu, Qian ^a   Liu, Meng ^a   Cheng, Neng Neng ^a   Li, Duan ^a   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Amylin; Glucagon like peptide 1; Goto Kakizaki rats; Insulin; Islet amyloid polypeptide; Type 2 diabetes

Indexed keywords

AMYLIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; MESSENGER RNA; RECOMBINANT HUMAN GLUCAGON LIKE PEPTIDE 1 [7-36];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE TOLERANCE TEST; GOTO KAKIZAKI RAT; HISTOLOGY; HORMONE RELEASE; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; POLYMERASE CHAIN REACTION; POSTPRANDIAL STATE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TREATMENT OUTCOME; TREATMENT PLANNING; WISTAR RAT;

EID: 42649091180     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00782.x     Document Type: Article

References (29)

1. 1 Marzban L, Park K, Verchere CB. Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 2003 ; 38: 347–51.
2. 2 Jaikaran ET, Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001 ; 1537: 179–203.
3. 3 Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuron‐peptide‐like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987 ; 84: 3881–5.
4. 4 Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β‐cells. Diabetes 1990 ; 39: 634–8.
5. 5 Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long‐recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999 ; 48: 241–53.
6. 6 Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G. Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest 2003 ; 33: 316–22.
7. 7 Verchere CB, D'Alessio DA, Prigeon RL, Hull RL, Kahn SE. The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. Diabetes 2000 ; 49: 1477–84.
8. 8 Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC, et al. Changes in amylin and amylin‐like peptide concentrations and β‐cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 1998 ; 21: 810–6.
9. 9 Dhanvantari S, Izzo A, Jansen E, Brubaker PL. Coregulation of glucagon‐like peptide‐1 synthesis with proglucagon and prohormone convertase 1 gene expression in enteroendocrine GLUTag cells. Endocrinology 2001 ; 142: 37–42.
10. 10 Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon‐like peptide 1 in type 2 diabetic patients. Diabetes 2001 ; 50: 609–13.
11. 11 Brubaker PL, Drucker DJ. Mini review: glucagon‐like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004 ; 145: 2653–9.
12. 12 Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6‐week course of glucagon‐like peptide 1 on glycaemic control, insulin sensitivity, and β‐cell function in type 2 diabetes: a parallel‐group study. Lancet 2002 ; 359: 824–30.
13. 13 Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP‐1 on glucose‐stimulated insulin secretion: effects on β‐cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003 ; 52: 380–6.
14. 14 Portha B, Serradas P, Bailbé D, Suzuki K, Goto Y, Giroix MH. β‐Cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 1991 ; 40: 486–91.
15. 15 Ostenson CG, Khan A, Abdel‐Halim SM, Guenifi A, Suzuki K, Goto Y, et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993 ; 36: 3–8.
16. 16 Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long‐acting GLP‐1 derivative NN2211 ameliorates glycemia and increases β‐cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002 ; 283: E745–52.
17. 17 Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose‐Rafizadeh C, et al. Glucagon‐like peptide‐1 can reverse the age‐related decline in glucose tolerance in rats. J Clin Invest 1997 ; 99: 2883–9.
18. 18 Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002 ; 20: 137–44.
19. 19 Rotondo F, Vidal S, Bell D, Horvath E, Kovacs K, Scheithauer BW, et al. Immunohistochemical localization of amylin in human pancreas, thyroid, pituitary and their tumors. Acta Histochem 2003 ; 105: 303–7.
20. 20 Leckström A, Ostenson CG, Efendiæ S, Arnelo U, Permert J, Lundquist I, et al. Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas 1996 ; 13: 259–67.
21. 21 Ferrannini E. Insulin resistance versus insulin deficiency in non‐insulin‐dependent diabetes mellitus: problems and prospects. Endocr Rev 1998 ; 19: 477–90.
22. 22 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity‐related health risk factors, 2001. JAMA 2003 ; 289: 76–9.
23. 23 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348: 383–93.
24. 24 Drucker DJ. Mini review: the glucagon‐like peptides. Endocrinology 2001 ; 142: 521–7.
25. 25 Kieffer TJ, Habener JF. The glucagon‐like peptides. Endocr Rev 1999 ; 20: 876–913.
26. 26 Deacon CF, Nauck MA, Toft‐Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon‐like peptide I are rapidly degraded from the NH 2 ‐terminus in type II diabetic patients and in healthy subjects. Diabetes 1995 ; 44: 1126–31.
27. 27 Leahy JL, Fineman MS. Impaired phasic insulin and amylin secretion in diabetes rats. Am J Physiol 1998 ; 275: E457–62.
28. 28 Cluck MW, Murphy LO, Olson J, Knezetic JA, Adrian TE. Amylin gene expression mediated by cAMP/PKA and transcription factors HNF‐1 and NFY. Mol Cell Endocrinol 2003 ; 210: 63–75.
29. 29 Gu Q, Gao X. Effect of recombined human glucagon‐like peptide‐1 on body weight, blood glucose metabolism and β‐cell function and mass in GK rat. Fudan Univ J Med Sci 2007 ; 34: 111–5.